Ann: Commencement of BNC210 Phase 2 Agitation Trial, page-4

OK, I missed that they'll recruit about 40 elderly patients.

Bit more digging.
Agitation affects 5M in the US, and is estimated to have US market potential of $1.6B.
PSTD 8.7-9M, $4.7B
GAD 7M, $2.7B
Others are:
Major Depressive Disorder 8-8.5M, $3.2B
Bipolar Disorder 3-3.5M, $1.5B
Panic Disorder 6.5-7M, $4.4B
SAD 17M, $2.5B

Results from Clinical study in GAD provide proof of biology for these indications.
There is a slide on anticipated Phase 3 trials for PTSD and GAD.
http://www.bioshares.com.au/presenations2017/s111rathjen.pdf
There is potential for rapid path to market (2021 for PTSD and 2023 for GAD), but it'll sit on the shelf until the Phase 3 trials gets funded. I guess management will just keep doing these small Phase 2 studies until they get a partner or get bought out.